AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Independent laboratory and Merck & Co., Inc., sign oncology research partnership.
2004 SEP 2 - (NewsRx.com & NewsRx.net) -- Pierre Fabre Medicament has signed a collaborative research, development and license agreement with Merck & Co., Inc., for F50035, Pierre Fabre Medicament's recombinant humanized antibody targeted against the insulin-like growth factor (IGF-1) receptor. F50035 is currently in preclinical development for the treatment of cancer.
Under the terms of the agreement, both partners will participate in a 3-year, renewable research program aimed at completing characterization of the antitumor activity of F50035 and identifying back-up antibodies.
Merck will be responsible for development and manufacturing of F50035. Merck is receiving worldwide marketing rights for F50035 and related antibodies, with Pierre Fabre Medicament maintaining exclusive rights to commercialize the product in France and certain other French-speaking countries. Financial terms were not disclosed.
The IGF-1 receptor is over-expressed in many tumor types, including those of the colon, breast and prostate, and it therefore is a potential target for the development of oncology drugs. The monoclonal antibody F50035 exhibits a novel mechanism of action. By targeting the IGF-1 receptor, F50035 is internalized by tumor cells, causing those cells to die. F50035 may have potential for use as a monotherapy or in conjunction with other drugs for the treatment of various cancers.
"This agreement with Merck underscores the relevance of our research approaches in this field, and demonstrates that innovation is not dependent upon the size of an organization," said Jacques Kusmierek, MD, Pierre Fabre Medicament's R & D director and president of the Pierre Fabre Research Institute.
"This collaborative research program enables researchers from the Pierre Fabre Immunology Center to benefit from the exceptional human, scientific and technological environment of Merck, and has the potential to lead to the development of a novel and targeted new anticancer ...
- Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development...
- Press release article from: PR Newswire December 22, 2008 700+ words
...Laboratories, Inc. and Pierre Fabre Medicament today announced that they...Chief Executive Officer of Pierre Fabre Medicament. "Forest has an excellent...product launch meeting About Pierre Fabre Medicament The Pierre Fabre Group...
- Cypress Bioscience Revises Milnacipran License With Pierre Fabre Medicament to...
- Press release article from: PR Newswire June 9, 2003 700+ words
...Milnacipran license agreement with Pierre Fabre Medicament, SA, Paris, France...United States and Canada. Pierre Fabre Medicament will continue to have the...Cypress has issued to Pierre Fabre Medicament one million shares of Cypress...
- Javlor(R) (Vinflunine) From Pierre Fabre Medicament Enters in Phase III...
- Press release article from: PR Newswire September 10, 2003 700+ words
...France, Sept. 10 /PRNewswire/ -- Pierre Fabre Medicament is announcing today the launch of two...and II) currently in phase I. About Pierre Fabre Medicament R&D Pierre Fabre Medicament, the business line for ethical pharmaceuticals...
- Pierre Fabre Medicament Signs License Agreement With Pharmagenesis for...
- Press release article from: PR Newswire March 17, 2003 700+ words
...signed an agreement with Pierre Fabre Medicament (PFM), a European company...Director of Oncology, Pierre Fabre Medicament. "We're interested in...pharmaceutical companies. Pierre Fabre Medicament is developing a second oncology...
- Bristol-Myers Squibb and Pierre Fabre Medicament S.A. Enter Into Agreement to...
- Press release article from: PR Newswire April 20, 2004 700+ words
...Myers Squibb Company and Pierre Fabre Medicament S.A., a privately held...Jean-Pierre Couzinier, Pierre Fabre Medicament Chief Operating Officer...deal were not disclosed. Pierre Fabre Medicament will be responsible for...
- B-MS licenses Pierre Fabre's Javlor.(Bristol-Myers Squibb)(Pierre Fabre...
- Newspaper article from: Pharma Marketletter April 26, 2004 700+ words
...entered into an agreement with France-headquartered Pierre Fabre Medicament SA to develop and commercialize the latter's anticancer...Korea and selected Southeast Asian territories. Pierre Fabre will be responsible for the development and marketing...
- Pierre Fabre submits MAA for milnacipran on strong Ph III data.(Pierre Fabre...
- Newspaper article from: Pharma Marketletter June 16, 2008 700+ words
Pierre Fabre Medicament presented positive data from a Phase III study of milnacipran fibromyalgia in adult patients. The French drugmaker also announced...
- Cypress Bioscience, Inc., Forest Laboratories, Inc. and Pierre Fabre Medicament...
- Press release article from: PR Newswire January 9, 2004 700+ words
...Laboratories, Inc. , and Pierre Fabre Medicament announced today that the...product's originator, Pierre Fabre Medicament, for indications in the...developed and marketed by Pierre Fabre Medicament as a dual-acting agent...